Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths
worldwide with about 600,000 patients dying from the disease annually. In 70–90%, HCC …

Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have
thus far been disappointing owing to a lack of robust stratification methods. Whole-genome …

Background Treatment of dysplastic Barrett's oesophagus prevents progression to
adenocarcinoma; however, the optimal diagnostic strategy for Barrett's oesophagus is unclear. The …

Background HCC predominantly develops in the condition of chronic inflammation that has
led to liver cirrhosis. A small proportion of patients with HCC is diagnosed in the non-cirrhotic …

Background Despite evidence for the association of distal gastric cancer (GC) with the H.
pylori infection, relevance of the infection for proximal GC is uncertain. Aims We analysed the …

AIM: To assess whether antibiotic resistance varies between the antrum and corpus of the
stomach of patients that are either Helicobacter pylori (H. pylori) therapy-naive or pre-treated. …

Background Non-invasive tools for gastric cancer screening and diagnosis are lacking.
Serological testing with the detection of pepsinogen 1 (PG1), pepsinogen 2 (PG2) and gastrin 17 …

Background & Aims Most patients with esophageal adenocarcinoma (EAC) present with de
novo tumors. Although this could be due to inadequate screening strategies, the precise …

… pylori antibiotic susceptibility in the period between January 2005 and May 2012. …
Malfertheiner P, Selgrad M, Bornschein J.Helicobacter pylori: clinical management.Curr …

Background & Aims Esophageal adenocarcinomas (EACs) are heterogeneous and often
preceded by Barrett’s esophagus (BE). Many genomic changes have been associated with …